Is Semaglutide with cagrilintide legal in the United Kingdom?

The rare blend whose combination has actually been trialled, at scale: co-administered cagrilintide and semaglutide produced 20.4% mean weight loss at week 68 against 3.0% on placebo in 3,417 participants. What research vendors sell under this description is not that product, at that ratio, from that supply chain, and gastrointestinal adverse events affected 79.6% of the combination group in the trial.

This page has to do two jobs at once, and keeping them separate is the whole point. First job: the combination is real and it works.

Mechanism: Semaglutide agonises the GLP-1 receptor. Cagrilintide is a long-acting amylin analogue acting on satiety through amylin receptor signalling in the hindbrain.

Regulatory history: The co-formulated combination has been trialled at phase 3 and is the subject of regulatory filings. A research chemical blend sold under its description is not that product and is not approved.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Semaglutide with cagrilintide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.